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Clinical comparison of dexmedetomidine and medetomidine for isoflurane balanced 1 
anaesthesia in horses  2 
 3 
Abstract 4 
Objective     To compare the effects of two balanced anaesthetic protocols (isoflurane – 5 
dexmedetomidine vs. medetomidine) on sedation, cardiopulmonary function and recovery in 6 
horses. 7 
 8 
Study design     Prospective, blinded, randomised clinical study. 9 
 10 
Animals     Sixty healthy adult warm blood horses undergoing elective surgery. 11 
 12 
Methods     Thirty horses each were sedated with dexmedetomidine 3.5 μg kg-1 (group DEX) 13 
or medetomidine 7 μg kg-1 (group MED) intravenously. After assessing and topping up 14 
sedation if necessary, anaesthesia was induced with ketamine/diazepam and maintained with 15 
isoflurane in oxygen/air and dexmedetomidine 1.75 μg kg-1 hour-1 or medetomidine 3.5 μg kg-16 
1
 hour
-1. Ringer’s lactate (7–10 mL kg-1 hour-1) and dobutamine were administered to 17 
maintain normotension. Controlled mechanical ventilation maintained end-tidal expired 18 
carbon dioxide pressures at 40–50 mmHg (5.3–6.7 kPa). Heart rate, invasive arterial blood 19 
pressure, inspired and expired gas composition and arterial blood gases were measured. 20 
Dexmedetomidine 1 μg kg-1 or medetomidine 2 μg kg-1 were applied for timed and scored 21 
recovery phase. Data were analysed using two-way repeated-measures analysis of variance 22 
(ANOVA) and chi-squared test. Significance was considered when p ≤ 0.05. 23 
 24 
Results     In group DEX, significantly more horses (n = 18) did not fulfil sedation criteria 25 
prior to induction and received one or more top-ups, whereas in group MED only two horses 26 
needed one additional bolus. Median total sedation doses (range) were dexmedetomidine 4 μg 27 
kg
-1
 (3.5–9) or medetomidine 7 μg kg-1 (7–9). During general anaesthesia, cardiopulmonary 28 
parameters did not differ significantly between groups. Recovery scores in group DEX were 29 
significantly better than in group MED. 30 
 31 
Conclusion and clinical relevance 32 
Horses receiving dexmedetomidine required more than 50% medetomidine dose to 33 
reach equivalent sedation. During isoflurane anaesthesia, cardiopulmonary function was 34 
comparable between the two groups. Recovery scores following dexmedetomidine were 35 
better compared to medetomidine. 36 
 37 
  38 
Introduction 39 
A balanced anaesthetic protocol with partial intravenous anaesthesia (PIVA) using two 40 
or more ancillary agents is a common concept in modern equine general anaesthesia (Gozalo-41 
Marcilla et al. 2014, 2015). It allows reducing the amount of volatile agents and therefore 42 
keeps undesirable effects to a minimum. Constant rate infusions (CRIs) of different alpha2-43 
adrenergic agonists in combination with isoflurane have been used in anaesthetised horses for 44 
this purpose (Ringer et al. 2007; Devisscher et al. 2010; Schauvliege et al. 2011; Marcilla et 45 
al. 2012; Pöppel et al. 2015). Furthermore, the analgesic effects of these drugs can improve 46 
recovery qualities (Bettschart-Wolfensberger & Larenza 2007; Gozalo-Marcilla et al. 2015). 47 
Medetomidine, a highly selective, short acting alpha2-adrenergic agonist [selectivity 48 
ratio (α2:α1) 1620:1] (Virtanen et al. 1988) has been shown to reduce the minimum alveolar 49 
concentration (MAC) of isoflurane and to provide rapid recoveries of good quality in ponies 50 
and horses (Bettschart-Wolfensberger et al. 2001; Ringer et al. 2007). Classic side effects of 51 
alpha2-adrenergic agonists including bradycardia, arrhythmias, decreases in cardiac output 52 
and increases in systemic vascular resistance have been documented for medetomidine 53 
(Bettschart-Wolfensberger et al. 1999a; Yamashita et al. 2000; Grimsrud et al. 2012). 54 
Compared to a CRI, more prominent side effects were described following an intravenous 55 
(IV) bolus (Bettschart-Wolfensberger et al. 1999a). However, within 30 minutes, when steady 56 
state conditions of medetomidine plasma levels were achieved (Bettschart-Wolfensberger et 57 
al. 1999b), an improvement of cardiopulmonary variables was demonstrated. Therefore, it 58 
was concluded that the infusion of 3.5 μg kg-1 hour-1 causes minimum cardiopulmonary 59 
depression, once the effects of a 5 μg kg-1 bolus have waned (Bettschart-Wolfensberger et al. 60 
1999a).  61 
A bolus of dexmedetomidine, the dextro-rotary and active enantiomer of 62 
medetomidine, showed a large volume of distribution at steady-state with a rapid clearance, 63 
resulting in a shorter plasma elimination half-live than medetomidine in horses (8 minutes for 64 
dexmedetomidine 10 μg kg-1 vs. 29 minutes for medetomidine 5 μg kg-1) (Grimsrud et al. 65 
2012; Rezende et al. 2015). A dexmedetomidine bolus has also shorter lasting 66 
cardiopulmonary effects without a decrease in heart rate (HR) compared to medetomidine 67 
(Bettschart-Wolfensberger et al. 1999b, 2005). The use of a dexmedetomidine CRI at a rate of 68 
1.75 μg kg-1 hour-1 in isoflurane anaesthetised horses under clinical circumstances produced 69 
limited cardiopulmonary effects, improving recovery qualities significantly (Marcilla et al. 70 
2012). 71 
Preliminary studies in horses by Bettschart-Wolfensberger et al. (2005) showed that 72 
medetomidine 7 μg kg-1 had equivalent sedative effects to dexmedetomidine 3.5 μg kg-1.  73 
Direct comparative clinical studies with dexmedetomidine at a 50% dose of 74 
medetomidine have been conducted in dogs (Granholm et al. 2007; Raszplewicz et al. 2013) 75 
and sheep (Kästner et al. 2001). 76 
The main purpose of the study was to compare two different PIVA protocols 77 
(isoflurane with either dexmedetomidine or medetomidine) in horses undergoing elective 78 
surgeries to assess the effects on sedation, cardiopulmonary parameters and recovery phase. 79 
The hypothesis of our study was that the sedation doses were expected to be similarly potent, 80 
with no unexpected side effects after either dexmedetomidine or medetomidine bolus. 81 
Moreover, based on the available pharmacokinetic data and previous clinical reports, fewer 82 
and shorter lasting cardiopulmonary effects with a lower incidence of partial pressure of 83 
oxygen (PaO2) < 80 mmHg (10.7 kPa) were hypothesised during dexmedetomidine CRI 84 
compared with medetomidine in isoflurane-anaesthetised horses. Safe recoveries were 85 
expected with both of the drugs.  86 
 87 
Material and methods 88 
 89 
Study design and animals 90 
This prospective randomised blinded clinical study was performed with the ethical approval 91 
of the local committee for animal experimentation (removed for blinding). Written owners’ 92 
consent was obtained. 93 
Sixty client-owned, non-food producing horses of various breeds presented for 94 
elective surgeries were included in the study. Inclusion criteria were body weight (≥ 200 kg), 95 
age (2–20 years), physical status ASA (American Society of Anaesthesiologists) 1 or 2 based 96 
on a physical examination, and procedure type (no surgery of the head region, no rope-97 
assisted recovery required). Food but not water was withheld for 10–16 hours prior to 98 
anaesthesia. Each patient was randomly assigned to either group DEX (dexmedetomidine) or 99 
MED (medetomidine) at the beginning of the experiment, using previously prepared opaque 100 
envelops opened by a person who was not involved in the study. Demographic data and body 101 
condition score (BCS) were recorded on a separate data sheet, BCS adapted from Carroll & 102 
Huntington 1988. All anaesthetic procedures were performed by the same experienced 103 
anaesthetist, who was unaware of the treatment at any time until the end of the study, 104 
including the recovery phase. 105 
 106 
Study protocol 107 
Sixty minutes prior to sedation, a jugular catheter was placed following desensitisation of the 108 
insertion site with 4 mL of mepivacaine 2% (removed for blinding). The horses received 109 
either cefquinome 1 mg kg
-1
 IV (removed for blinding) or a combination of sodium 110 
benzylpenicillin 30,000 I.E. kg
-1
 (removed for blinding) and gentamicin 9 mg kg
-1
 IV 111 
(removed for blinding) as antibiotherapy and flunixin meglumine 1.1 mg kg
-1
 IV (removed for 112 
blinding) for soft tissue surgeries or phenylbutazone 4 mg kg
-1
 IV (removed for blinding) for 113 
orthopaedic surgeries as anti-inflammatory drugs.  114 
Each horse was premedicated with acepromazine 0.03 mg kg
-1
 (removed for blinding) 115 
intramuscularly (IM) 30 minutes prior to the start of the study. Immediately before induction 116 
of anaesthesia, horses were sedated with dexmedetomidine 3.5 μg kg-1 IV (removed for 117 
blinding) or medetomidine 7 μg kg-1 (removed for blinding) IV, depending on group 118 
allocation. Medication was prepared by a veterinarian not involved in the study and diluted 119 
with sodium chloride to a total volume of 20 mL and 5 mL for sedation and top-ups, 120 
respectively. One-third of the dose was administered as a bolus in the stable, then the mouth 121 
was rinsed and the horse walked into the induction area, where the remaining two-thirds were 122 
injected slowly over 2 minutes. Five minutes later, depth of sedation was assessed and 123 
considered adequate when the criteria listed in Table 1, adapted from Taylor et al. (2014), 124 
were fulfilled. If one or more conditions were not present, a top-up of dexmedetomidine 0.5 125 
μg kg-1 or medetomidine 1 μg kg-1 was administered IV, depending on group allocation. 126 
Sedation was re-evaluated after 3 minutes. This procedure was repeated once more if 127 
necessary. If sedation remained insufficient, a third extra bolus of dexmedetomidine 1 μg kg-1 128 
or medetomidine 2 μg kg-1 was given IV over 2 minutes to ensure a good level of sedation 129 
prior to anaesthesia induction. The time needed for bolus application and until induction of 130 
anaesthesia as well as the total amount of required sedation were recorded.  131 
Anaesthesia was induced with diazepam 0.02 mg kg
-1
 IV (removed for blinding) and 132 
ketamine 2.2 mg kg
-1
 (removed for blinding) mixed in one syringe. This was considered as 133 
anaesthesia time point zero (t0). Once the horses were recumbent and the tracheas intubated 134 
(silicone tubes, I.D. 22 to 30 mm), they were hoisted onto a padded surgery table and attached 135 
to a large animal circle system (removed for blinding). Controlled mechanical ventilation 136 
(CMV) of the lungs was commenced immediately to maintain end-tidal expired carbon 137 
dioxide pressures (PΕ‘CO2) of 40–50 mmHg (5.3–6.7 kPa). Anaesthesia was maintained 138 
using isoflurane (removed for blinding) delivered in oxygen and air [fraction of inspired 139 
oxygen (FIO2) between 0.45–0.55]. Every 5 minutes, depth of anaesthesia and isoflurane 140 
supply was assessed and readjusted subjectively by the main investigator, unaware of the 141 
treatment, based on clinical parameters. Dexmedetomidine 3.5 μg kg-1 hour-1 or 142 
medetomidine 7 μg kg-1 hour-1 for group DEX and MED, respectively, were started 143 
immediately after positioning the animal on the surgery table, delivered IV by an infusion 144 
pump (removed for blinding). Direct measurement of MAP and collection of arterial blood 145 
samples were performed via a catheter inserted into the facial artery. The catheter was linked 146 
to a pressure transducer, placed at the level of the heart with the scapulohumeral joint as a 147 
reference point and zeroed to ambient pressure. Heart rate, MAP, FIO2, PE′CO2 and ET′Iso 148 
were recorded every 5 minutes. Dobutamine up to 1.25 μg kg-1 minute-1 (removed for 149 
blinding), administered by an infusion pump (removed for blinding) and Ringer’s lactated 150 
solution 7–10 mL kg-1 hour-1 (removed for blinding) were given IV to maintain the mean 151 
arterial blood pressure (MAP)  > 70 mmHg. In order to keep the MAP values stable, the rate 152 
of dobutamine was minimally readjusted every 5 minutes based on a prepared rate scale in 153 
dependence on the MAP (60–64 mmHg: 1.25 μg kg-1 minute-1; 65–70: 1; 71–75: 0.8; 76–80: 154 
0.7; 81–85: 0.5; 86–90; 0.25; > 90: 0). If the MAP remained below 65 mmHg or if the HR 155 
increased to a value higher than 1.5 times HR at t30, a 500 mL IV bolus of hetastarch 156 
(removed for blinding) was given in addition to the dobutamine infusion. This bolus 157 
application was repeated every 5 minutes, until MAP was > 65 mmHg. If nystagmus or 158 
incessant fighting against the ventilator occurred, ketamine 0.1 mg kg
-1
 IV was administered. 159 
In case of sudden movement thiopental 0.5–1 mg kg-1 IV (removed for blinding) was 160 
administered. At time points t30, t60, t90 and t150 arterial and venous blood samples were drawn 161 
anaerobically, using pre-heparinized syringes (removed for blinding) and analysed 162 
immediately (RAPIDPoint, Siemens, Germany). Analysis included pH, venous and arterial 163 
oxygen and carbon dioxide partial pressures (PvCO2, PvO2, PaCO2, PaO2), base excess (BE) 164 
and electrolytes (Na
+
, K
+
, Ca
++
, Cl
-
) as well as arterial lactate (Lac). Total haemoglobin of the 165 
arterial blood sample was measured separately (removed for blinding). If a PaO2 < 80 mmHg 166 
(10.7 kPa) was detected, FIO2 was changed to 1.0 and salbutamol 2 μg kg
-1
 was administered 167 
intratracheally. These horses were excluded from further blood gas analysis. The ratio of 168 
arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FIO2) was calculated 169 
later for t30, t60, t90 and t150 under exclusion of those horses with FIO2 = 1.0. 170 
 Thirty minutes prior to the end of anaesthesia, morphine 0.1 mg kg
-1
 IM (removed for 171 
blinding) was administered. At the end, all infusions and CMV were stopped and horses were 172 
hoisted from the table and placed in a padded recovery box. From the moment of the lateral 173 
positioning of the horse, the recovery timing was started. Ventilation was assisted using a 174 
demand valve until the horses started to breathe spontaneously. Subsequently, 175 
dexmedetomidine 1 μg kg-1 (group DEX) or medetomidine 2 μg kg-1 (group MED) was 176 
administered IV slowly over 2 minutes. If horses either moved or showed excessive 177 
nystagmus and were in danger of an untimely recovery, the dose of either dexmedetomidine 178 
or medetomidine was doubled. Oxygen was administered (10 L minute
-1
) through the 179 
endotracheal tube (ETT). The tracheas were extubated once the horses either started to show 180 
nystagmus or regained their swallow reﬂex. Before removing the ETT, 5 mL phenylephrine 181 
0.15% drops (removed for blinding) were instilled into each nasal cavity. Horses were 182 
allowed to recover without assistance. Times required until extubation, first limb movement 183 
and time to attain sternal and standing positions were noted. The main anaesthetist assessed 184 
the recovery quality. It was graded on a standard scoring 5-point scale (Table 2) with a score 185 
of 1 representing the best recovery (Vettorato et al. 2010; Bettschart-Wolfensberger et al. 186 
2011; Gozalo-Marcilla et al. 2012).  187 
 188 
Statistical analysis 189 
Sample size calculations indicated, that 27 horses per group were necessary to show a 190 
statistically significant reduction from 50% to 15% incidence of horses with PaO2 of < 80 191 
mmHg (10.7 kPa). The average value of 50% incidence for that low PaO2 values in horses 192 
anaesthetised under similar conditions as in the present study was based on previous reports 193 
(Kalchofner et al. 2006; Ringer et al. 2007). 194 
Data distribution was tested with the Kolmogorov-Smirnoff test of normality. 195 
Depending on normality, the t-test or the Mann-Whitney test were used to assess significant 196 
differences between groups in weight, age, anaesthesia duration, recovery times and scores. 197 
Repeatedly measured parameters were analysed using a two-way repeated- measures analysis 198 
of variance (ANOVA) for differences between groups and over time. Chi-squared test was used 199 
to evaluate significant group differences between required doses of sedation and intra-200 
anaesthetically injected ketamine or thiopental. Significance was considered when p ≤ 0.05. 201 
Statistical analysis was performed using SPSS 19 (removed for blinding) except for repeated-202 
measures ANOVA tests that were performed with SigmaStat 3.5 (removed for blinding). 203 
Results of parametric data are expressed as mean ± standard deviation (SD) and results of 204 
nonparametric data as median and (range). 205 
 206 
Results 207 
Figure 1 shows the number of included and excluded horses per group throughout the entire 208 
study period. Six horses in DEX and four horses in MED were treated with salbutamol 2 μg 209 
kg
-1
 intratracheally and FIO2 was set to 1.0. Partial pressure of O2 was > 80 mmHg (10.7 kPa) 210 
30 minutes after these interventions in all horses. One horse in group DEX was euthanized 211 
after 115 minutes due to bad prognosis for the intra-operatively detected orthopaedic problem, 212 
and was consequently not available for data analysis during recovery. Two horses in group 213 
MED were excluded from data analysis of the general anaesthesia, as one suffered from an 214 
incident of pulmonary air-embolism and one received atropine 6 μg kg-1 IV. This was due to a 215 
HR of 15 bpm. Bradycardia resolved following atropine. In group MED, only the horse 216 
suffering from air-embolism was excluded from data analyses during the recovery, as in this 217 
case the study protocol could not be followed. 218 
No significant differences in age (DEX: 7.8 ± 5.2 years; MED: 8 ± 5.4 years), body 219 
weight (DEX: 534 ± 88 kg; MED: 507 ± 71 kg), BCS, gender or type of recumbency were 220 
identified. The total duration of anaesthesia was not different between groups (DEX: 145 ± 221 
50.8 minutes; MED: 151 ± 36 minutes). In group DEX, a higher number of horses (n = 18) 222 
did not fulfil the sedation criteria and needed one or more top-ups (p < 0.001), whereas only 223 
two horses needed one additional bolus in group MED (Fig. 1). In group DEX seven horses 224 
did not meet sedation criteria after three top-ups following the protocol described. These 225 
horses were sedated slowly to effect with dexmedetomidine 1 μg kg-1 minute-1 until sedation 226 
was considered deep enough for induction of general anaesthesia. The median dose of 227 
sedation necessary to fulfil sedation criteria prior to anaesthesia induction was 4 μg kg-1 (3.5–228 
9) in group DEX and 7 μg kg-1 (7–9) in group MED. The time from the start of sedation to 229 
induction of anaesthesia was longer in DEX with 15 (9.5–35) minutes compared to 11 (9.5–230 
13) minutes in MED, respectively (p < 0.001). 231 
No significant difference was found between groups regarding mean ET′Iso 232 
concentrations (Mean ± SEM; DEX: 1.2 ± 0.02 %, MED: 1.1 ± 0.02 %, p = 0.36). 233 
Nevertheless, group-independent changes over time were significant with ET′Iso increasing 234 
over time compared to t5 (p < 0.001). Figure 2 and Table 3 display cardiopulmonary 235 
parameters emphasising significant group differences of MAP at t15 (p = 0.009) and t20 (p = 236 
0.029). A group-independent increase over time compared to t5 was found for HR (p < 0.001) 237 
and a decrease over time for MAP (p < 0.001).  238 
There was no significant difference between the groups in the mean dobutamine 239 
infusion rate [DEX: 0.6 ± 0.2 μg kg-1 minute-1, MED: 0.5 ± 0.2 μg kg-1 minute-1 (p = 0.76)]. 240 
An equal number of horses (n = 17) in group DEX and MED required one or several boli of 241 
ketamine. Six horses in DEX and three horses in MED were given a single dose of 0.5 or 1 242 
mg kg
-1
 thiopental, either to allow intubation (four in DEX, three in MED) or due to limb or 243 
ear movement during surgery (two in DEX). Information about BE, pH, electrolytes, Lac and 244 
haemoglobin is given in Table 3. 245 
All horses started to breathe spontaneously within 3–4 minutes after disconnection 246 
from the breathing system, which timed the start of administration of the post sedation.  247 
Times related to recovery did not differ significantly between groups, with recorded time 248 
spans in minutes (range) as the following: time to extubation DEX: 14 (4–21), MED: 18 (3–249 
20) (p = 0.12); time to sternal recumbency: DEX 39 (0–77), MED: 38 (0–73) (p = 0.93); time 250 
from sternal to standing DEX 22 (1–66), MED: 14 (0.5–63) (p = 0.22); total time to standing 251 
DEX: 56 (26–118), MED: 58 (32–93) (p = 0.26). Recovery scores were better with DEX (1 252 
(1–4) compared to MED (2 (1–4)) (p = 0.042) (Fig. 3). Four horses in DEX and one horse in 253 
MED were given an additional bolus of either dexmedetomidine or medetomidine for 254 
recovery (Fig. 1).  255 
  256 
Discussion 257 
The results of the present study showed that horses receiving dexmedetomidine at 50% dose 258 
rate of medetomidine required more additional doses for sedation prior to anaesthesia 259 
induction than those receiving medetomidine. Cardiopulmonary function was maintained 260 
within clinically acceptable levels during general anaesthesia with both drugs. Moreover, 261 
recovery qualities were better in horses receiving dexmedetomidine.  262 
In order to sedate the horses before induction of general anaesthesia, 263 
dexmedetomidine did not seem to be a reliable drug at the doses reported here. The sedation 264 
doses were chosen following the experimentally presumed equivalence of dexmedetomidine 265 
at 50% dose rate of medetomidine in dogs and sheep, as comparative studies in horses were 266 
lacking at the time of study design (Kuusela et al. 2000; Kästner et al. 2001; Granholm et al. 267 
2007). By then, the only study available regarding dexmedetomidine, reported the dose used 268 
in the present study (Bettschart-Wolfensberger et al. 2005). Later on, other authors used 3.5 269 
μg kg-1 IV dexmedetomidine prior to anaesthesia induction and 27.5 % (Marcilla et al. 2012) 270 
or 60 % (Marly-Voquer et al. 2016) of horses needed additional sedation to achieve deep 271 
sedation, as considered necessary before ketamine anaesthesia induction by most authors.  272 
The absence of deep sedation in many horses with the dose of dexmedetomidine used 273 
in this study questions the previously reported equipotency of dexmedetomidine 3.5 μg kg-1 to 274 
medetomidine 7 μg kg-1 in horses (Bettschart-Wolfensberger 2005). The aforementioned 275 
shorter plasma elimination time of dexmedetomidine compared to medetomidine may have 276 
contributed to this, as it could have led to plasma levels already falling beyond levels causing 277 
deep sedation in individual horses at time of sedation scoring, resulting in the higher number 278 
of dexmedetomidine top-ups (Grimsrud et al. 2012; Rezende et al. 2015). In awake horses 279 
receiving dexmedetomidine CRIs, a substantial inter-horse variation in pharmacokinetic 280 
parameters was observed, with remarkable differences in sedation levels directly related to 281 
plasma levels of dexmedetomidine (Ranheim et al. 2015). This is in contrast to the previously 282 
reported stable plasma levels of medetomidine (Bettschart-Wolfensberger et al. 1999b), which 283 
might offer further explanation of the cardiopulmonary and recovery quality – related 284 
differences observed between the two drugs. 285 
For both drugs compared in this study, typical alpha2-adrenergic agonist associated 286 
cardiopulmonary effects were recorded following induction of anaesthesia (Bettschart-287 
Wolfensberger et al. 1999a; Kuusela et al. 2000), but cardiopulmonary function remained 288 
within clinically acceptable limits using dobutamine CRI and fluid substitution. Despite the 289 
higher bolus doses for sedation with dexmedetomidine, MAP values at time points t15 and t20 290 
were statistically significantly higher with medetomidine than with dexmedetomidine. This 291 
was probably a consequence of shorter plasma half-life of dexmedetomidine leading to 292 
quicker establishment of steady state plasma levels (Bettschart-Wolfensberger et al. 1999a; 293 
Grimsrud et al. 2012; Rezende et al. 2015) with minimal effect on cardiopulmonary function. 294 
Further studies comparing the plasma levels and pharmacokinetic profiles of the two drugs 295 
combined with ketamine and followed by isoflurane would be necessary, in order to evaluate 296 
the exact differences and the subsequent effects on the cardiopulmonary system.  297 
No differences in ET′Iso were detected between groups and values were comparable 298 
with previous studies using the similar study designs (Kalchofner et al. 2009; Devisscher et 299 
al. 2010; Schauvliege et al. 2011; Marcilla et al. 2012). The clinical variables used here to 300 
assess anaesthetic depth are subjective and may have led to biased values of ET′Iso. 301 
Nevertheless, as the anaesthetist was always the same and unaware of the group allocation, 302 
this approach seemed justified to detect differences between the two groups. An objective 303 
scoring system to evaluate the plane of anaesthesia could have been used to make these 304 
results more reliable (Enderle et al. 2008; Gozalo-Marcilla et al. 2013). 305 
Recoveries from general anaesthesia were better and more successful at the first 306 
attempt in horses receiving dexmedetomidine compared with those treated with 307 
medetomidine. An improvement in recovery quality was also seen when comparing 308 
dexmedetomidine with saline (Marcilla et al. 2012). Better recoveries with dexmedetomidine 309 
may be the result of a shorter sedative and muscle relaxant effect in comparison to 310 
medetomidine (Grimsrud et al. 2012; Rezende et al. 2015). Nevertheless, it has to be kept in 311 
mind, that the horses of group DEX received additional post sedation in 4 cases, whereas this 312 
was only necessary in 1 horse in group MED, which might reduce the direct comparability of 313 
the two groups in regards to recovery quality.  314 
This study may have been impaired by two major limitations. First, the non-objective 315 
way of assessing anaesthetic depth, which probably prevented us from detecting slight 316 
differences in isoflurane requirements between groups. Furthermore, the exclusion of the 317 
blood gas variables of ten horses with PaO2 < 80 mmHg (10.7 kPa) where inspired oxygen 318 
fraction had to be increased, which led to a reduced number of data for statistical analysis. 319 
In conclusion, dexmedetomidine at 50% dose of medetomidine was not equisedative 320 
to medetomidine in horses. Dose rates to reach intended sedation before induction of 321 
anaesthesia were more individually variable with dexmedetomidine than with medetomidine. 322 
Cardiopulmonary function during general anaesthesia was almost identical and within 323 
clinically accepted ranges in both groups. Recoveries from general anaesthesia were of better 324 
quality in horses receiving dexmedetomidine, without any differences in recovery related 325 
times. 326 
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  415 
Figure 1   Flow diagram of the progress representing number of horses analysed during 416 
sedation, general anaesthesia and recovery. Reasons for exclusions are given in brackets. For 417 
sedation prior to induction, number of horses receiving additional sedative boli (termed top-418 
up) necessary to fulfil sedation criteria is given. Numbers of horses receiving additional post 419 
sedation for recovery (DEX: 1 μg kg-1; MED: 2 μg kg-1) are listed at the bottom. IV, 420 
intravenously; n, number of horses; FIO2, fraction of inspired oxygen 421 
Figure 2   Heart rates (HR) and mean arterial blood pressures (MAP) in horses during 422 
dexmedetomidine isoflurane (group DEX) or medetomidine isoflurane (group MED) 423 
balanced anaesthesia (mean ± SD). Significant time points are marked with *. Represented on 424 
the x–axis are minutes after anaesthesia induction and number of horses per group; nD, 425 
number of horses in group DEX; nM, number of horses in group MED (reductions due to 426 
different durations of anaesthesia) 427 
Figure 3   Recovery scores in horses following dexmedetomidine isoflurane (group DEX) or 428 
medetomidine isoflurane (group MED) balanced anaesthesia. Groups differed significantly (p 429 
= 0.042) 430 
  431 
Table 1   Criteria used to assess depth of sedation (adapted from Taylor et al. 2014; 432 
Evaluation of sedation for standing clinical procedures in horses using detomidine combined 433 
with buprenorphine)  434 
 
Sedation criteria 
 
 
1   Head height lower than withers (eyes as bench mark) 
2   Lower lip atonic 
3   No reaction to stimulation with a pen, when touching the inside of the ears  
435 
Table 2   Scoring system used to assess recovery from anaesthesia 436 
 
Score awarded 
 
 
Description of recovery 
 
  
1 Very good, standing at the first attempt 
2 Good, two attempts until standing 
3 More than two attempts, horse remains calm, minimal ataxia when 
standing 
4 Bad, several attempts to get up, horse becomes excited or in panic, 
risk of injury 
5 Very bad, recovery resulting in injury of the horse 
  437 
 438 
Table 3   Mean ± SD of venous and arterial blood gas values, ratio of arterial partial pressure 439 
of oxygen to fraction of inspired oxygen (PaO2/FIO2), pH, arterial lactate concentrations 440 
(Lac), total haemoglobin (Hb), arterial base excess (BE) and electrolytes in horses with 441 
dexmedetomidine isoflurane (group DEX) or medetomidine isoflurane (group MED) 442 
balanced anaesthesia. Significant differences (p < 0.05) between groups are indicated by * 443 
and significant changes over time are indicated with ♯444 
 445 
 t30 t60 t90 t150 Significant differences, p-value 
Venous PCO2 Dex  (mmHg) 49.50±5.5 52.11±4.1 53.05±5.4 55.33±6.2 ♯, p < 0.001 
Venous PCO2 Med 
 
Venous PCO2 Dex  (kPa) 
Venous PCO2 Med 
 
51.68±3.0 
6.4±0.7 
6.7±0.4 
52.59±4.6 
6.8±0.5 
6.8±0.6 
53.60±4.7 
6.9±0.7 
7.0±0.6 
55.13±5.5 
7.2±0.8 
7.2±0.7 
 
 
 
Venous PO2 Dex 
♯ 
(mmHg) 45.33±7.8 49.52±7.0 51.54±8.3 49.17±6.6 ♯, p < 0.001 
Venous PO2 Med 
♯ 
Venous PO2 Dex 
♯
 (kPa)
 
Venous PO2 Med 
♯
 
48.95±6.8 
5.9±1.0 
6.4±0.9 
52.48±6.5 
6.4±0.9 
6.8±0.8 
53.47±7.1 
6.7±1.1 
7.0±0.9 
56.49±9.1 
6.4±0.9 
7.3±1.2 
 
 
 
Arterial PCO2 Dex 
♯ 
(mmHg) 47.98±4.8 50.13±4.3 51.44±4.7 52.92±3.1 ♯, p < 0.001 
Venous PCO2 Med 
♯ 
Venous PCO2 Dex 
♯
 (kPa) 
Venous PCO2 Med 
♯
 
48.73±4.56 
6.2±0.6 
6.3±0.6 
50.83±4.5 
6.5±0.6 
6.6±0.6 
51.8±4.6 
6.7±0.6 
6.7±0.6 
53.57±5.6 
6.9±0.4 
7.0±0.7 
 
 
 
Arterial PO2 Dex 
♯ 
(mmHg) 159.70±53.49 154.01±49.39 154.95±51.01 146.43±33.14 ♯, p = 0.005 
Venous PCOMed 
♯ 
Venous PCODex 
♯
 (kPa) 
Venous PCOMed 
♯
 
153.03±42.95 
20.8±7 
19.9±5.6 
146.14±43.58 
20.0±6.4 
19±5.7 
147.16±40.90 
20.1±6.6 
19.1±5.3 
161.15±24.04 
19.0±4.3 
20.9±3.1 
 
 
 
PaO2/FIO2 Dex 
♯
 314±102 301±92 304±100 289±59 ♯, p = 0.003 
PaO2/FIO2 Med 
♯ 
304±93 288±83 295±85 291±78  
pH Dex 
♯ 
 7.37±0.03 7.36±0.03 7.36±0.03 7.37±0.03  
pH Med 
 
7.38±0.04 7.36±0.03 7.37±0.04 7.37±0.04  
Lac Dex 
♯ 
 1.36±0.31 1.59±0.38 1.59±0.39 1.65±0.64 ♯, p < 0.001 
Lac Med 
 
1.43±0.41 1.71±0.39 1.69±0.42 1.57±0.31  
Hb Dex 
♯ 
 11.59±1.32 11.08±1.20 10.69±1.50 10.49±1.41 * t150, p = 0.02  
Hb Med 
 
12.11±1.72 11.78±1.65 11.59±1.79 12.16±2.17 ♯, p < 0.001 
BE Dex 
♯ 
 1.73±2.07 1.98±2.01 2.70±1.91 4.32±1.6 ♯, p < 0.001 
BE Med 
 
2.21±2.14 2.23±2.25 3.25±1.95 4.41±2.42  
Electrolytes      
   Na
+
  Dex 
   Na
+
  Med 
133.2±1.64 
130±2.10 
133.75±1.72 
134.83±2.43 
134.05±1.83 
135.23±2.34 
134.67±2.55 
135.71±2.85 
 
 
 
   K
+
    Dex 
   Na
+
  Med 
 
   Ca
++ 
Dex 
   Na
+
  Med 
 
   Cl
– 
  Dex 
   Na
+ 
 Med
 
3.52±0.24 
3.54±0.22 
 
1.40±0.06 
1.43±0.06 
 
98.86±2.71 
99.21±2.3 
3.44±0.24 
3.51±0.27 
 
1.37±0.05 
1.40±0.07 
 
99.03±1.87 
99.55±2.18 
3.45±0.28 
3.48±0.21 
 
1.35±0.05 
1.39±0.07 
 
99.40±2.18 
99.38±2.29 
3.50±0.37 
3.52±0.28 
 
1.33±0.05 
1.36±0.09 
 
99.5±3 
99.54±2.9 
♯, p = 0.001 
 
 
♯, p < 0.001 
PaO2, PaCO2 / PvO2, PvCO2, arterial and venous oxygen and carbon dioxide partial pressures; Lac, arterial lactate concentration (mmol L
-1
); Hb, total 446 
hemoglobine g dL
-1
; BE, arterial base excess (mmol L
-1
); Na
+
, ionised sodium (mmol L
-1
); K
+
, ionised potassium (mmol L
-1
); Ca
++
, ionised calcium (mmol L
-1
); 447 
Cl
-
 , ionised chloride (mmol L
-1
)448 
 449 
